Selank and Semax get filed together as research peptides with reported nootropic properties, yet they descend from unrelated parent molecules and the published record describes opposite subjective directions for them. Selank, and by extension the acetylated N-Acetyl Selank, is a synthetic analog of tuftsin, a fragment of the immunoglobulin G molecule; Semax is a synthetic analog of the ACTH(4-10) fragment. Both came out of Russian research programs and both carry the same stabilizing tail, which explains some of the behavioral overlap despite the different lineage.
| Attribute | N-Acetyl Selank | Semax |
|---|---|---|
| Parent molecule | Tuftsin, an IgG fragment | ACTH(4-10) fragment |
| Reported direction | Calming, anxiolytic | Stimulating, focus-forward |
| Stabilizing motif | Proline-glycine-proline tail | Proline-glycine-proline tail |
| Regulatory status | Not an approved medicine | Not an approved medicine |
Selank derives from the immune peptide tuftsin and is reported as calming, while Semax derives from an ACTH(4-10) fragment and is reported as stimulating, yet neither is an approved medicine across most of the world.
The point most often confused when Semax is grouped with Selank is its parentage: the published record traces Semax to adrenocorticotropic hormone, not to tuftsin. The finished molecule is a heptapeptide, and its stabilizing tail is a durability modification rather than a new pharmacological group.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, built from the ACTH(4-10) fragment rather than from tuftsin.
Semax is documented for a profile that leans toward activation, attention, and neuroprotection rather than the calming character attributed to Selank. The recurring mechanistic thread in the research is neurotrophin upregulation, and that same thread carries an evidence caveat, since much of the supporting work sits below the level of large human trials.
Semax is reported to raise BDNF and NGF expression in the hippocampus, though much of the supporting evidence is animal research or smaller non-Western clinical studies rather than large controlled trials.
The clearest separation in the record is the direction of the state each is reported to produce. Selank documents on the calming side and Semax on the activating side, and each carries the mirror-image overshoot risk of the other.
| Dimension | Selank | Semax |
|---|---|---|
| State direction | Anxiolytic, stress-buffering | Focus-forward, energizing |
| Reported use case | Anxiety, overstimulation | Flat focus, low mental drive |
| Mechanistic lean | GABAergic and serotonergic tone | Neurotrophic, monoaminergic |
| Overshoot risk | Too soft for those wanting drive | Restlessness or a wired feeling |
The literature separates the two by direction of effect, with Selank reported as anxiolytic and stress-buffering and Semax reported as focus-forward and activating.
The relationship is parallel: N-Acetyl Semax is to Semax what N-Acetyl Selank is to Selank, an analog carrying an acetyl group on the N-terminus of the same parent peptide. The published rationale frames acetylation as a durability improvement, not a change in the peptide's character.
N-terminal acetylation caps the peptide's free amino end to slow enzymatic degradation, extending the effective window while preserving the parent peptide's character rather than adding a new mechanism.
In the published framing the decision collapses to one question about the goal: whether the deficit is too much arousal or too little. The record treats the calm-versus-drive map as a starting point, with timing and individual sensitivity to stimulation weighting it further.
Reports map Selank to over-arousal and Semax to under-arousal, with time of day and an individual's sensitivity to stimulation weighting the choice.
The stacking logic in user reports is that the two peptides sit at opposite ends of the arousal spectrum, so the pairing is an attempt to draw focus from Semax while Selank keeps the accompanying edge in check. That complementary calm-plus-drive target is something neither peptide is documented to deliver alone, and the practice rests on anecdote rather than trial data.
The Selank-plus-Semax stack targets a complementary calm-plus-drive state, but it rests on user self-report and mechanistic reasoning, with no controlled trial establishing that the pair is safe or synergistic.
Both peptides carry the same set of caveats, and the published record holds that these travel with any comparison of the two. Regulatory status, evidence strength, sourcing, and long-term safety each pull the honest register toward measured, provisional language.
Neither Semax nor Selank, including the acetylated forms, is an approved medicine across most of the world, and both are commonly sold labeled for research use rather than for human consumption.
Educational use only. This article describes what the published scientific and clinical literature reports about N-Acetyl Selank and Semax. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
